You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨抗流感概念股拉昇 流感疫苗接種大增
格隆匯 09-23 10:10
格隆匯9月23日丨抗流感概念股拉昇,華蘭生物漲近4%,瑞普生物和普洛藥業漲約3.5%。每年9月至10月,是接種流感疫苗的最佳時機。近期在北京、甘肅、四川、吉林等地,受新冠肺炎疫情影響,今年秋冬流感疫苗接種需求比往年同期有所增加。業內人士認為,接種流感疫苗或可減少因罹患流感而到醫院就診的人數,避免流感和新冠肺炎疫情疊加,減輕防控壓力。各地應加大流感疫苗的生產調配,提前安排接種人員和場地,合理應對今年的流感季。據西南證券統計,截至8月(今年的流感疫苗自7月開始批簽發),今年流感疫苗共計批簽發1054萬支,同比增長52%。三價流感疫苗獲批簽發629萬支,同比增長12%,佔比60%。四價流感疫苗獲批簽發425萬支,同比增長224%,佔比40%。四價獲批簽發流感疫苗中,華蘭生物批簽發量為289萬支,佔比68%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account